Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer: an international, multicentre, retrospective study
Background - Lutetium-177 (177Lu) prostate-specific membrane antigen (177Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after 177Lu-PSMA to enhance its clinical implementation are yet to be identified. We aimed...
Gespeichert in:
| Hauptverfasser: | , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
July 8, 2021
|
| In: |
The lancet. Oncology
Year: 2021, Jahrgang: 22, Heft: 8, Pages: 1115-1125 |
| ISSN: | 1474-5488 |
| DOI: | 10.1016/S1470-2045(21)00274-6 |
| Online-Zugang: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1016/S1470-2045(21)00274-6 Verlag, lizenzpflichtig, Volltext: https://www.sciencedirect.com/science/article/pii/S1470204521002746 
|
| Verfasserangaben: | Andrei Gafita, Jeremie Calais, Tristan R Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B Rettig, Ebrahim S Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S Hofman, Wolfgang P Fendler, Matthias Eiber |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 177433447X | ||
| 003 | DE-627 | ||
| 005 | 20220820060521.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 211018s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/S1470-2045(21)00274-6 |2 doi | |
| 035 | |a (DE-627)177433447X | ||
| 035 | |a (DE-599)KXP177433447X | ||
| 035 | |a (OCoLC)1341422038 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Gafita, Andrei |e VerfasserIn |0 (DE-588)121703773X |0 (DE-627)1728846714 |4 aut | |
| 245 | 1 | 0 | |a Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer |b an international, multicentre, retrospective study |c Andrei Gafita, Jeremie Calais, Tristan R Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B Rettig, Ebrahim S Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S Hofman, Wolfgang P Fendler, Matthias Eiber |
| 246 | 3 | 3 | |a Nomograms to predict outcomes after 177 Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer |
| 264 | 1 | |c July 8, 2021 | |
| 300 | |a 11 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Im Text ist "177" hochgestellt | ||
| 500 | |a Gesehen am 18.10.2021 | ||
| 520 | |a Background - Lutetium-177 (177Lu) prostate-specific membrane antigen (177Lu-PSMA) is a novel targeted treatment for patients with metastatic castration-resistant prostate cancer (mCRPC). Predictors of outcomes after 177Lu-PSMA to enhance its clinical implementation are yet to be identified. We aimed to develop nomograms to predict outcomes after 177Lu-PSMA in patients with mCRPC. - Methods - In this multicentre, retrospective study, we screened patients with mCRPC who had received 177Lu-PSMA between Dec 10, 2014, and July 19, 2019, as part of the previous phase 2 trials (NCT03042312, ACTRN12615000912583) or compassionate access programmes at six hospitals and academic centres in Germany, the USA, and Australia. Eligible patients had received intravenous 6·0-8·5 GBq 177Lu-PSMA once every 6-8 weeks, for a maximum of four to six cycles, and had available baseline [68Ga]Ga-PSMA-11 PET/CT scan, clinical data, and survival outcomes. Putative predictors included 18 pretherapeutic clinicopathological and [68Ga]Ga-PSMA-11 PET/CT variables. Data were collected locally and centralised. Primary outcomes for the nomograms were overall survival and prostate-specific antigen (PSA)-progression-free survival. Nomograms for each outcome were computed from Cox regression models with LASSO penalty for variable selection. Model performance was measured by examining discrimination (Harrell's C-index), calibration (calibration plots), and utility (patient stratification into low-risk vs high-risk groups). Models were validated internally using bootstrapping and externally by calculating their performance on a validation cohort. - Findings - Between April 23, 2019, and Jan 13, 2020, 414 patients were screened; 270 (65%) of whom were eligible and were divided into development (n=196) and validation (n=74) cohorts. The median duration of follow-up was 21·5 months (IQR 13·3-30·7). Predictors included in the nomograms were time since initial diagnosis of prostate cancer, chemotherapy status, baseline haemoglobin concentration, and [68Ga]Ga-PSMA-11 PET/CT parameters (molecular imaging TNM classification and tumour burden). The C-index of the overall survival model was 0·71 (95% CI 0·69-0·73). Similar C-indices were achieved at internal validation (0·71 [0·69-0·73]) and external validation (0·72 [0·68-0·76]). The C-index of the PSA-progression-free survival model was 0·70 (95% CI 0·68-0·72). Similar C-indices were achieved at internal validation (0·70 [0·68-0·72]) and external validation (0·71 [0·68-0·74]). Both models were adequately calibrated and their predictions correlated with the observed outcome. Compared with high-risk patients, low-risk patients had significantly longer overall survival in the validation cohort (24·9 months [95% CI 16·8-27·3] vs 7·4 months [4·0-10·8]; p<0·0001) and PSA-progression-free survival (6·6 months [6·0-7·1] vs 2·5 months [1·2-3·8]; p=0·022). - Interpretation - These externally validated nomograms that are predictive of outcomes after 177Lu-PSMA in patients with mCRPC might help in clinical trial design and individual clinical decision making, particularly at institutions where 177Lu-PSMA is introduced as a novel therapeutic option. - Funding - Prostate Cancer Foundation. | ||
| 700 | 1 | |a Calais, Jeremie |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grogan, Tristan R |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hadaschik, Boris |e VerfasserIn |4 aut | |
| 700 | 1 | |a Wang, Hui |e VerfasserIn |4 aut | |
| 700 | 1 | |a Weber, Manuel |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sandhu, Shahneen |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kratochwil, Clemens |d 1978- |e VerfasserIn |0 (DE-588)134026276 |0 (DE-627)559871686 |0 (DE-576)300262787 |4 aut | |
| 700 | 1 | |a Esfandiari, Rouzbeh |e VerfasserIn |4 aut | |
| 700 | 1 | |a Tauber, Robert |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zeldin, Anna |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rathke, Hendrik |d 1986- |e VerfasserIn |0 (DE-588)1151445495 |0 (DE-627)1011715392 |0 (DE-576)497748223 |4 aut | |
| 700 | 1 | |a Armstrong, Wesley R |e VerfasserIn |4 aut | |
| 700 | 1 | |a Robertson, Andrew |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thin, Pan |e VerfasserIn |4 aut | |
| 700 | 1 | |a D'Alessandria, Calogero |e VerfasserIn |4 aut | |
| 700 | 1 | |a Rettig, Matthew B |e VerfasserIn |4 aut | |
| 700 | 1 | |a Delpassand, Ebrahim S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Haberkorn, Uwe |d 1959- |e VerfasserIn |0 (DE-588)1022913905 |0 (DE-627)717331245 |0 (DE-576)366166352 |4 aut | |
| 700 | 1 | |a Elashoff, David |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herrmann, Ken |e VerfasserIn |4 aut | |
| 700 | 1 | |a Czernin, Johannes |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hofman, Michael S |e VerfasserIn |4 aut | |
| 700 | 1 | |a Fendler, Wolfgang P |e VerfasserIn |4 aut | |
| 700 | 1 | |a Eiber, Matthias |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t The lancet. Oncology |d London : The Lancet Publ. Group, 2000 |g 22(2021), 8 vom: Aug., Seite 1115-1125 |h Online-Ressource |w (DE-627)325349770 |w (DE-600)2035574-9 |w (DE-576)100517544 |x 1474-5488 |7 nnas |a Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer an international, multicentre, retrospective study |
| 773 | 1 | 8 | |g volume:22 |g year:2021 |g number:8 |g month:08 |g pages:1115-1125 |g extent:11 |a Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer an international, multicentre, retrospective study |
| 856 | 4 | 0 | |u https://doi.org/10.1016/S1470-2045(21)00274-6 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.sciencedirect.com/science/article/pii/S1470204521002746 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20211018 | ||
| 993 | |a Article | ||
| 994 | |a 2021 | ||
| 998 | |g 1022913905 |a Haberkorn, Uwe |m 1022913905:Haberkorn, Uwe |d 910000 |d 911400 |e 910000PH1022913905 |e 911400PH1022913905 |k 0/910000/ |k 1/910000/911400/ |p 19 | ||
| 998 | |g 1151445495 |a Rathke, Hendrik |m 1151445495:Rathke, Hendrik |d 910000 |d 911400 |e 910000PR1151445495 |e 911400PR1151445495 |k 0/910000/ |k 1/910000/911400/ |p 12 | ||
| 998 | |g 134026276 |a Kratochwil, Clemens |m 134026276:Kratochwil, Clemens |d 910000 |d 911400 |e 910000PK134026276 |e 911400PK134026276 |k 0/910000/ |k 1/910000/911400/ |p 8 | ||
| 999 | |a KXP-PPN177433447X |e 3990915819 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"relHost":[{"disp":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer an international, multicentre, retrospective studyThe lancet. Oncology","recId":"325349770","titleAlt":[{"title":"The lancet <London> / Oncology"}],"language":["eng"],"type":{"media":"Online-Ressource","bibl":"periodical"},"pubHistory":["0.2000 -"],"origin":[{"dateIssuedKey":"2000","publisherPlace":"London","publisher":"The Lancet Publ. Group","dateIssuedDisp":"2000-"}],"title":[{"title":"The lancet","title_sort":"lancet","partname":"Oncology"}],"part":{"extent":"11","issue":"8","year":"2021","pages":"1115-1125","text":"22(2021), 8 vom: Aug., Seite 1115-1125","volume":"22"},"id":{"eki":["325349770"],"issn":["1474-5488"],"zdb":["2035574-9"]},"physDesc":[{"extent":"Online-Ressource"}],"note":["Gesehen am 22.09.2021"]}],"note":["Im Text ist \"177\" hochgestellt","Gesehen am 18.10.2021"],"physDesc":[{"extent":"11 S."}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"id":{"eki":["177433447X"],"doi":["10.1016/S1470-2045(21)00274-6"]},"language":["eng"],"title":[{"title":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer","subtitle":"an international, multicentre, retrospective study","title_sort":"Nomograms to predict outcomes after 177Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer"}],"titleAlt":[{"title":"Nomograms to predict outcomes after 177 Lu-PSMA therapy in men with metastatic castration-resistant prostate cancer"}],"person":[{"display":"Gafita, Andrei","given":"Andrei","family":"Gafita","role":"aut"},{"display":"Calais, Jeremie","given":"Jeremie","family":"Calais","role":"aut"},{"role":"aut","family":"Grogan","given":"Tristan R","display":"Grogan, Tristan R"},{"given":"Boris","display":"Hadaschik, Boris","family":"Hadaschik","role":"aut"},{"display":"Wang, Hui","given":"Hui","family":"Wang","role":"aut"},{"given":"Manuel","display":"Weber, Manuel","family":"Weber","role":"aut"},{"role":"aut","display":"Sandhu, Shahneen","given":"Shahneen","family":"Sandhu"},{"role":"aut","family":"Kratochwil","given":"Clemens","display":"Kratochwil, Clemens"},{"role":"aut","family":"Esfandiari","given":"Rouzbeh","display":"Esfandiari, Rouzbeh"},{"family":"Tauber","display":"Tauber, Robert","given":"Robert","role":"aut"},{"role":"aut","family":"Zeldin","display":"Zeldin, Anna","given":"Anna"},{"family":"Rathke","display":"Rathke, Hendrik","given":"Hendrik","role":"aut"},{"family":"Armstrong","display":"Armstrong, Wesley R","given":"Wesley R","role":"aut"},{"role":"aut","given":"Andrew","display":"Robertson, Andrew","family":"Robertson"},{"family":"Thin","display":"Thin, Pan","given":"Pan","role":"aut"},{"display":"D'Alessandria, Calogero","given":"Calogero","family":"D'Alessandria","role":"aut"},{"family":"Rettig","given":"Matthew B","display":"Rettig, Matthew B","role":"aut"},{"role":"aut","display":"Delpassand, Ebrahim S","given":"Ebrahim S","family":"Delpassand"},{"role":"aut","given":"Uwe","display":"Haberkorn, Uwe","family":"Haberkorn"},{"role":"aut","family":"Elashoff","given":"David","display":"Elashoff, David"},{"role":"aut","family":"Herrmann","display":"Herrmann, Ken","given":"Ken"},{"role":"aut","given":"Johannes","display":"Czernin, Johannes","family":"Czernin"},{"family":"Hofman","display":"Hofman, Michael S","given":"Michael S","role":"aut"},{"role":"aut","family":"Fendler","display":"Fendler, Wolfgang P","given":"Wolfgang P"},{"role":"aut","family":"Eiber","display":"Eiber, Matthias","given":"Matthias"}],"recId":"177433447X","origin":[{"dateIssuedKey":"2021","dateIssuedDisp":"July 8, 2021"}],"name":{"displayForm":["Andrei Gafita, Jeremie Calais, Tristan R Grogan, Boris Hadaschik, Hui Wang, Manuel Weber, Shahneen Sandhu, Clemens Kratochwil, Rouzbeh Esfandiari, Robert Tauber, Anna Zeldin, Hendrik Rathke, Wesley R Armstrong, Andrew Robertson, Pan Thin, Calogero D'Alessandria, Matthew B Rettig, Ebrahim S Delpassand, Uwe Haberkorn, David Elashoff, Ken Herrmann, Johannes Czernin, Michael S Hofman, Wolfgang P Fendler, Matthias Eiber"]}} | ||
| SRT | |a GAFITAANDRNOMOGRAMST8202 | ||